LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
SEOUL, South Korea, May 18, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic...
LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma
Expanding track record by signing contracts with various global companies across Asia and Europe SEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced on June 19, 2025 that it has signed a contract manufacturing agreement for...